Navigation Links
DelMar Pharmaceuticals Gives Quarterly Shareholder Update
Date:11/11/2013

I/II dose-escalation trial designed to assess the safety and preliminary efficacy of our lead product candidate, VAL-083, for the treatment of GBM.  

The results reported to date have shown promising drug activity and we believe that VAL-083 represents a potential new treatment option for brain tumor patients who have failed or are unlikely to benefit from today's standard of care.  More than half of patients fail the currently approved treatments.

The goal of our current clinical trial is to establish the optimal VAL-083 dosing regimen for both safety and efficacy in a U.S.-based GBM patient population. This dose would then be advanced into a Phase III GBM registration study, which we expect to commence in mid-2014 . During the past quarter, the U.S. Food and Drug Administration (FDA) undertook a detailed safety review of the Phase I/II trial and allowed us to accelerate our dose escalation program.  While this modification is unlikely to shorten the trial due to the length of our discussions with the FDA throughout this review, we should realize significant cost savings as fewer patients will be exposed to sub-optimal doses within the escalation study. We will present additional data from the ongoing Phase I/II trial during the Society for NeuroOncology (SNO) Annual Meeting on Friday November 22, 2013. 

We Are Strengthening Our Intellectual Property Portfolio
We have filed a broad portfolio of new patent applications to protect our intellectual property. Our patent applications claim compositions and methods related to the use of VAL-083 and related compounds as well as methods of synthesis and quality controls for the manufacturing process of VAL-083. In addition to our patent portfolio, VAL-083 has been granted Orphan Drug protection for the treatment of glioma, including GBM, in both the U.S. and Europe.  The orphan drug designation provides VAL-0
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
2. DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
3. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
4. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
5. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
7. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
8. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
10. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
11. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 You,re visiting the dentist for ... when he or she says you need a root ... you may have several questions and feel apprehensive about ... know it,s nothing to worry about. The Pennsylvania Dental ... alleviate any anxiety the public may have surrounding this ...
(Date:12/19/2014)... , Dec. 19, 2014 In ... research and marketing communication tools are essential for ... competitive – consequently consumers, desires, preferences, and unmet ... environment, market research groups across all industries are ... communication tools. However, the adoption of new market ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... addition of the "Micro Market Monitor: North ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is progressing steadily, which has resulted in fueling ... market. The main purpose of these dermatology devices ...
Breaking Medicine Technology:Root Canals Have Become More Routine 2Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3
... Nov. 1, 2011 Daylight Saving Time comes to an end ... altering sleep patterns. Sixty percent of Americans say that they experience ... the National Sleep Foundation,s 2011 Sleep in America poll, and for ... This season, fall back into bed for not only ...
... Calif., Nov. 1, 2011 Telik, Inc. (Nasdaq: ... studies on Telintra and related analogs at the 2011 ... and Cancer Therapeutics in San Francisco, California.  Details of ... Novel Ezatiostat analogues disrupt binding of GSTP1 to ...
Cached Medicine Technology:Keep the Time Change From Disrupting Your Rest With Sleep Formula 39™ 2Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2
(Date:12/21/2014)... 21, 2014 Khanna Vision Institute is ... at the Aspen Helicopters holiday event for underprivileged kids. ... with sleigh, flown by an aspen helicopter pilot. In ... Santa with sleigh was visible.(please see accompanying video). Helicopter ... Dr.Khanna has helped many pilots with Pi in eye ...
(Date:12/21/2014)... York, New York (PRWEB) December 21, 2014 ... ) and other product liability claims involving a ... incretin mimetics continue to move forward in a ... Court, Southern District of California, Bernstein Liebhard LLP ... the Court has established a data cut-off date ...
(Date:12/21/2014)... The number of Mirena lawsuits ( ... underway in New Jersey, Bernstein Liebhard LLP reports. , ... involving the birth control IUD have now been filed ... by women who allege spontaneous migration of the device, ... and other complications they were inadequately warned about by ...
(Date:12/21/2014)... 2014 Parker & Sons, Inc. a ... plumbing and other similar home contractor services announces a ... to its expert contracting services. The company is considered ... been serving Arizona for well over 40 years. Parker ... best in quality customer service to the residents and ...
(Date:12/21/2014)... Theme and plugin developers from ... for Final Cut Pro X entitled ProMotion. , “ProMotion ... with absolute ease.” Said Christiana Austin, CEO of Pixel ... to easily animate their media inside FCPX.” , Pixel ... to animate pictures, videos, logos, and more with absolute ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2
... release is available in Spanish . , What ... a disease? What affects the ideas and beliefs that patients ... Granada have developed a test for measuring and assessing ... enable the development of clinical psychological treatments much more efficient ...
... HealthDay Reporter , WEDNESDAY, Oct. 20 (HealthDay News) ... for new warnings on the labels of widely used hormonal ... risk of heart disease and diabetes in the men who ... it was reviewing the prostate cancer drugs known as gonadotropin-releasing ...
... Calif.) A study of the options for reducing ... treated for precancerous cervical lesions found that an annual ... Joy Melnikow, professor in the Department of Family ... strategies for the 500,000 American women diagnosed and treated ...
... Computed tomography colonography (CTC) otherwise known as virtual ... optimal colonoscopy is limited, according to a study in ... ( www.ajronline.org ). The study was performed ... and Tuba City Regional Health Care Center in Tuba ...
... Oct. 20 -- Scientists and engineers from around the world ... N.Y. next week to discuss some of the latest breakthroughs ... the development of new materials, and medicine. Journalists are ... the 94th annual meeting of the Optical Society (OSA), which ...
... Oct. 20 (HealthDay News) -- Fatalism, a belief that life,s ... have some of the lowest cancer screening rates in the ... more likely than white women to believe that cancer is ... with cancer, the researchers found. Karla Espinosa de los ...
Cached Medicine News:Health News:The impact of chronic diseases on patients also depends on their perception of the disease 2Health News:FDA Calls for New Warnings on Some Prostate Cancer Drugs 2Health News:FDA Calls for New Warnings on Some Prostate Cancer Drugs 3Health News:Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment 2Health News:Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 2Health News:Colorful brains, cooling lasers, disease-detecting lights and more 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 4Health News:Colorful brains, cooling lasers, disease-detecting lights and more 5Health News:Colorful brains, cooling lasers, disease-detecting lights and more 6Health News:Colorful brains, cooling lasers, disease-detecting lights and more 7Health News:Colorful brains, cooling lasers, disease-detecting lights and more 8Health News:Colorful brains, cooling lasers, disease-detecting lights and more 9Health News:Colorful brains, cooling lasers, disease-detecting lights and more 10Health News:Colorful brains, cooling lasers, disease-detecting lights and more 11Health News:Colorful brains, cooling lasers, disease-detecting lights and more 12Health News:Fatalistic Attitudes May Keep Hispanic Women From Cancer Tests 2
... HEp-2000 ANA uses a patented HEp-2 ... to increase the sensitivity to SS-A/Ro autoantibodies, ... Several independent studies have been published worldwide ... increased sensitivity to SS-A/Ro autoantibodies when used ...
... The ANA and ENA assays ... patients negative for antinuclear antibodies, which ... diseases such as Systemic lupus erythematosus ... disease, progressive systemic sclerosis, scleroderma, polymyositis, ...
... The ANA and ENA assays can ... negative for antinuclear antibodies, which are ... such as Systemic lupus erythematosus (Lupus), ... progressive systemic sclerosis, scleroderma, polymyositis, dermatomyositis, ...
... Indirect Fluorescence Assay (IFA) for IgG ... for the qualitative and semi-quantitative detection ... in human serum. Detection of ANA ... an aid in the diagnosis of ...
Medicine Products: